Inovio Pharmaceuticals Inc., a leading developer of therapeutic and preventive vaccines, today announced that its SynCon ™ therapeutic DNA vaccine (INO-5150) for prostate cancer demonstrated positive immune responses in monkeys.
The company said the results support similarly strong, antigen-specific and sustainable T cell levels in previously reported data from earlier animal studies. Inovio said the new data reinforces its plan to a start phase I clinical trial for INO-5150 by the middle of next year.
Dr. J. Joseph Kim, Ph.D., president & CEO of Inovio, emphasized the potential of the vaccine in human models.
“The immune response data achieved by our SynCon™ prostate cancer vaccine in this large animal study is exceptional. It reinforces the repeatedly and consistently strong, long-lasting immune responses achieved by Inovio’s DNA vaccine platform against multiple cancers as well as other diseases,” Dr. Kim stated in the press release. “We are optimistic about the potential of this therapeutic vaccine in our planned prostate cancer human study and broadly speaking for cancers in general, including our currently progressing cervical cancer and leukemia phase II clinical studies.”
Inovio is currently manufacturing clinical grade INO-5150 with the goal of launching its planned phase I study in mid-2012. The company plans on enrolling a total of 148 patients across 25 study centers in the US., Korea, South Africa, Australia and Canada.
Inovio is currently conducting a phase II study for its cervical cancer vaccine. The randomized, placebo controlled, double blind study as designed to evaluate the effects of VGX-3100 treatment on the clearance of moderate or severe cervical intraepithelial neoplasia (CIN 2/3) cervical lesions.
For more information visit www.inovio.com
Let us hear your thoughts below: